Induction of the Nrf2-driven Antioxidant Response Confers Neuroprotection During Mitochondrial Stress in vivo

Andy Y. Shih12*, Sophie Imbeault12*, Vilte Barakauskas12, Heidi Erb12, Lei Jiang12, Ping Li12 and Timothy H. Murphy123

1Kinsmen Laboratory, Department of Psychiatry, 2Brain Research Center, 3Department of Physiology University of British Columbia, Vancouver, BC Canada. * These authors contributed equally to this work.

Running Title: Nrf2-mediated neuroprotection from mitochondrial stress

Correspondence addressed to: Timothy H. Murphy, Ph.D. Department of Psychiatry, University of British Columbia, 4N1-2255 Wesbrook Mall, Vancouver, BC Canada V6T 1Z3. Tel: 604-822-0705; Fax: 604-822-7981; Email: thmurphy@interchange.ubc.ca

NF-E2 related factor (Nrf2) controls a pleiotropic cellular defense, where multiple antioxidant/detoxification pathways are upregulated in unison. Although small molecule inducers of Nrf2 activity have been reported to protect neurons in vitro, whether similar pathways can be accessed in vivo is not known. We have investigated whether in vivo toxicity of the mitochondrial complex II inhibitor 3-nitropropionic acid (3-NP) can be attenuated by constitutive and inducible Nrf2 activity. The absence of Nrf2 function in Nrf2-/- mice resulted in 3-NP hypersensitivity that became apparent with time and increasing dose, causing motor deficits and striatal lesions on a more rapid time-scale than identically treated Nrf2+/+ and Nrf2 +/- controls. Striatal succinate dehydrogenase activity, the target of 3-NP, was inhibited to the same extent in all genotypes by a single acute dose of 3-NP, suggesting that brain concentrations of 3-NP were similar. Dietary supplementation with the Nrf2 inducer tert-butylhydroquinone attenuated 3-NP toxicity in Nrf2 +/- mice, but not Nrf2-/-, confirming the Nrf2-specific action of the inducer in vivo. Increased Nrf2 activity alone was sufficient to protect animals from 3-NP toxicity since intrastriatal adenovirus-mediated Nrf2 overexpression significantly reduced lesion size compared to GFP overexpressing controls. In cultured astrocytes, 3-NP was found to increase Nrf2 activity leading to antioxidant response element-dependent gene expression providing a potential mechanism for the increased sensitivity of Nrf2-/- animals to 3-NP toxicity in vivo. We conclude that Nrf2 may underlie a feedback system limiting oxidative load during chronic metabolic stress.

Introduction

The Cap ‘n’ Collar transcription factor NF-E2 related factor (Nrf2) controls the coordinated expression of important antioxidant and detoxification genes (Phase 2 genes) through a promotor sequence termed the antioxidant response element (ARE) (1-3). Phase 2 genes work in synergy to constitute a pleiotropic cellular defense that scavenges reactive oxygen/nitrogen species (ROS/RNS), detoxifies electrophiles and xenobiotics, and maintains intracellular reducing potential (4-8). Normally, Nrf2 is sequestered in the cytoplasm by the actin-bound regulatory protein, Keap1 (9,10). Multiple cysteine residues allow Keap1 to act as a molecular ‘switch’ by responding to electrophiles/ROS with a conformational change, which releases Nrf2 for nuclear translocation and activation of Phase 2 gene expression (11-13). Thus, Nrf2 provides an important mechanistic link between oxidative stress leading to cell death and antioxidant gene expression supporting cell survival.

Nrf2-/- mice are particularly maladapted when challenged with toxicity paradigms such as hyperoxic lung injury, butylated hydroxytoluene-induced acute pulmonary injury, acetaminophen-induced liver toxicity, benzo[a]pyrene-induced tumourigenesis in the forestomach, or cigarette smoke-induced emphysema (14-19). Although the protective function of Nrf2 is apparent in peripheral tissues, the role of Nrf2 in the brain, where substantial ROS/RNS...
production can occur due to a high rate of metabolism, remains unclear. We hypothesize Nrf2 function is critical for supporting neuronal survival during neurodegenerative disease when aberrant ROS/RNS production is known to be exacerbated (20). To study the effect of Nrf2 activity on in vivo neurodegeneration, we systemically administered 3-nitropropionic acid (3-NP), an irreversible inhibitor of succinate dehydrogenase (SDH), which causes striatal-specific cell loss leading to impairment of motor function 3-NP models (21). Metabolic inhibition by 3-NP produces oxidative stress in the brain through multiple mechanisms: 1.) ATP depletion, membrane depolarization, increased neuronal/glial glutamate release, over-activation of N-methyl-D-aspartate ionotropic glutamate receptors, accumulation of intracellular Ca^{2+}, and excessive mitochondrial ROS production (22,23). 2.) Secondary activation of Ca^{2+}-dependent enzymes such as phospholipase A2 (production of inflammatory mediators) and nitric oxide synthase (peroxynitrite formation) (24,25). 3.) Excessive dopamine release, which can generate H$_2$O$_2$ when metabolized (26).

Upregulation of Nrf2 activity in the brain is an attractive strategy for mitigating ROS/RNS overproduction during neurodegenerative disease. To test the hypothesis that augmentation of Nrf2 could protect neurons in vivo, we increased Nrf2 activity in the brain using dietary administration of the small molecule inducer, tert-butylhydroquinone (tBHQ) or adenoviral-mediated overexpression of Nrf2 (6). In previous studies, these treatments protected cultured neurons from toxicity paradigms that mimic aspects of in vivo neurodegeneration, such as glutamate-induced glutathione depletion, dopamine toxicity, direct exposure to H$_2$O$_2$, metabolic inhibition with mitochondrial toxins (rotenone), platelet activating factor-induced inflammatory responses, and increased intracellular Ca$^{2+}$ (6,27-30). Importantly, neuronal cultures derived from Nrf2$^{-/-}$ mice show increased susceptibility to neurotoxicity paradigms and were not protected by Nrf2 inducers, but can be rescued by overexpression of Nrf2 (28,31).

Our in vitro and in vivo data suggest that Nrf2 activation is a protective response to counter the toxic effects of metabolic inhibition and ROS/RNS production in the brain. Loss of Nrf2 function in Nrf2$^{-/-}$ mice exacerbated motor deficits and striatal lesions caused by 3-NP administration. Conversely, pre-activation of the Nrf2 response (using dietary administration of a Nrf2 inducer or viral gene transfer) attenuated 3-NP toxicity. Nrf2 activation may be a viable strategy to prime the antioxidant capacity of the brain, thereby decreasing injury caused by progressive neurodegeneration.

**Materials and Methods**

**Chemicals:** All chemicals were obtained from Sigma-Aldrich unless otherwise stated.

**In vivo 3-NP dosage regimen:** All experiments were approved by the U.B.C. Animal Care Committee and were conducted in strict accordance with guidelines set by the Canadian Council on Animal Care. Adult male Wistar rats (Charles River, Canada) (250-350 g) and Nrf2$^{-/-}$ mice (C57Bl/6 / SV129 background), originating from the laboratory of Dr. Yuet Wai Kan (32), were maintained in a 12 h light-dark cycle with food and water ad libitum. 3-NP was prepared in 0.1 M phosphate buffered saline (PBS) and adjusted to pH 7.4 with NaOH and maintained at 4°C for up to 1 week. For Nrf2 mice, a similar number of males and females (aged 10-16 weeks) were used. The 3-NP treatment regimen consisted of 9 total intraperitoneal (i.p.) injections with one injection given every 12 h at successively increasing doses: 20 mg/kg x 4, 40 mg/kg x 4, 60 mg/kg x 1 (33). No significant difference was observed between males and females with respect to behaviour, weight loss, or lesion size in this study. For rats, daily i.p. injections of 3-NP (n = 10) or PBS control (n = 10) were administered by one of two dosage regimens: (40 mg/kg, 40 mg/kg, 20 mg/kg) or (40 mg/kg, 20 mg/kg, 20 mg/kg, 20 mg/kg), each regimen resulting in the animal receiving a total of 100 mg/kg of 3-NP over 3 or 4 days. Both dosage regimens were tested in order to overcome possible preconditioning effects due to adenovirus injection. However, the average lesion volumes produced by the two dosage regimens were not different after statistical analyses (two-tailed t-test), and the groups were pooled. Since virus was injected unilaterally we conservatively only included in the study animals with measurable 3-NP lesions by histology. Animals were sacrificed 24 h after the last injection or upon displaying severe motor behaviour deficits such as recumbence (complete loss of motor control).

**Semi-qualitative Behaviour Scoring of Mice:** A detailed description for the assessment of 3-NP induced motor deficits was described previously (33). Briefly, the scoring system involved the evaluation of 5 major symptoms each with a 3-tiered scoring scale (0, 1, or 2), with 0 = normal behaviour and 2 = severe deficit. Symptoms included: a.) hind limb clasp, b.) reduced general locomotor activity, c.) hind limb dystonia (increased muscle tone leading to abnormal
the principle of Cavalieri (volume = $s_1d_1 + s_2d_2 + s_3d_3$) was used to calculate lesion volume according to Fisher. Lesion volume was calculated using standard protocols on 40 μm sections mounted on SuperFrost Plus slides (Fisher). Lesion volume was calculated according to the principle of Cavalieri (volume = $s_1d_1 + s_2d_2 + s_3d_3 + s_4d_4$) where $s =$ lesion surface area and $d =$ distance between 2 sections. Adjacent 20 μm slide-mounted sections were examined for Fluorojade (Histochem Inc.) staining as previously described (34). CV sections were scanned at 600 DPI on an Epson desktop scanner and lesion area was quantified by an experimenter blinded to the animal genotypes using ImageJ software (National Institute of Health). Four anatomical levels of the striatum were examined (Bregma +1.10 mm, +0.40 mm, -0.26 mm, -0.92 mm) according to the mouse brain atlas (35). Fluorojade-positive neurons were only assessed in the core of the striatal lesion. Fluorojade images were collected using a Retiga Exi CCD camera (QImaging). For rats, perfusions cryosectioning and CV staining were performed as described for mice. Histological and Fluorojade staining was performed with standard protocols on 40 μm sections mounted on SuperFrost Plus slides (Fisher). Lesion volume was calculated according to the principle of Cavalieri (volume = $s_1d_1 + s_2d_2 + s_3d_3 + s_4d_4$) where $s =$ lesion surface area and $d =$ distance between 2 sections. Adjacent 20 μm slide-mounted sections were examined for Fluorojade (Histochem Inc.) staining as previously described (34). CV sections were scanned at 600 DPI on an Epson desktop scanner and lesion area was quantified by an experimenter blinded to the animal genotypes using ImageJ software (National Institute of Health). Four anatomical levels of the striatum were examined (Bregma +1.10 mm, +0.40 mm, -0.26 mm, -0.92 mm) according to the mouse brain atlas (35). Fluorojade-positive neurons were only assessed in the core of the striatal lesion. Fluorojade images were collected using a Retiga Exi CCD camera (QImaging). For rats, perfusions cryosectioning and CV staining were performed as described for mice. Total lesion volumes were calculated using the following formula $V_t = V_1 + V_2 + \ldots + V_n$, where $V_n = rhr_{n-1}r_n + r_{n-1}r_n + r_n^2)/3$, where $h$ is the distance between 2 sections and $r$ is the radius of the lesion area using sections from Bregma 1.70 mm, 1.2 mm, 0.70 mm, 0.2 mm, -0.26 mm, and -0.80 mm according to the rat brain atlas (36).

**Succinate Dehydrogenase Assay:** Male or female mice from each genotype were acutely injected with 60 mg/kg 3-NP and were always paired with PBS-injected littermates of the same sex and genotype. After 2 h, the mice were euthanized with halothane and then decapitated. Brains were washed with ice-cold PBS and striata and cortices were dissected from a 2 mm brain-matrix slice at approximately Bregma +1.0 mm. Crude mitochondrial samples were prepared by dounce homogenization in 0.25 M sucrose, 1 mg/ml bovine serum albumin (BSA), 1 mM EDTA, pH 7.4. To collect the mitochondria, the homogenate was centrifuged at 4°C, 600 × g for 5 min. The supernatant was then re-centrifuged at 7,200 × g at 4°C for 10 min. The supernatant was aspirated, and the mitochondrial pellet was resuspended in the same buffer. SDH activity was assayed immediately using a protocol based on studies by Pennington et al. (37). Briefly, the reaction consisted of 0.1 M potassium phosphate buffer (pH 7.4), 0.1 M succinate, 0.05 M sucrose, 2 mg/mL p-Iodonitrotetrazolium chloride (prepared fresh), and 125 μg/mL crude mitochondria (final concentrations in 400 μL reaction volume) and incubated for 20 min at 37°C. The formazan mixture was vortexed before measurement on a microplate reader at 490 nm. Protein concentration was measured using the bicinchoninic acid method (Pierce). Brain homogenates were serially diluted for the assay and data analyses were performed on values within the linear range of the SDH reaction. We also used 4 Nrf2+/- mice to examine the dose-response relationship between acute SDH inhibition and various injected 3-NP concentrations (20 mg/kg, 40 mg/kg or 60 mg/kg). Both 20 mg/kg and 40 mg/kg doses produced little or no change 2 h after injection, compared to PBS injection (data not shown), whereas 60 mg/kg produced an observable decrease in activity. The 60 mg/kg dose was used for further SDH bioassays.

**Preparation of tBHQ-supplemented diets:** All rats and mice were normally fed Lab Diet 5001, which contains no tBHQ, but trace amounts of BHA for preserving animal fats (2 ppm). For tBHQ feeding, food pellets were powdered in a coffee grinder and dry mixed with 1% (w/w) tBHQ. Distilled water was added to the powder (equal v/w), mixed, and reshaped into food pellets. The pellets were then baked at 60°C for 3 h. Control food was processed in the same fashion without the addition of tBHQ. Initially, we determined 5% tBHQ in diet was not consumed by Nrf2-/- mice (n = 3), and 0.5% tBHQ, although consumed, only slightly preserved motor function during 3-NP treatment (n = 3). For these reasons, a concentration of 1% tBHQ was used in all further feeding experiments.

**Enzyme Assays for brain tissue:** Brain and liver tissue was dissected in ice-cold PBS and homogenized with 10 strokes of a dounce homogenizer in tissue buffer containing 25 mM Tris (pH 7.4) and 250 mM sucrose. Crude homogenates were centrifuged at 15,000 g for 10 min at 4°C. Tissue homogenate supernatants were collected and promptly assayed for enzyme activity. NQO1 enzyme activity was determined by calculating the dicumarol-
sensitive fraction of DCPIP reduction (38). Reactions consisting of 25 mM Tris-HCl buffer (pH 7.4) with 0.7 mg/mL BSA, 5 μM FAD, 200 μM NADH, 30 μg/mL protein, with and without 20 μM dicumarol were pre-incubated for 10 min at 25°C (final concentrations in 200 μL reaction volume). DCPIP was then added to a final concentration of 36 μM (20 μL volume), and the reaction was monitored at 540 nm. The extinction coefficient for DCPIP was 2.1 x 10⁴ M⁻¹ cm⁻¹. The GST assay consisted of 1 mM 1-chloro-2,4-dinitrobenzene (CDNB), 1 mM glutathione, and 100 μg/mL protein at 37°C in 100 mM potassium phosphate buffer (pH 6.5) (final concentration in 150 μL reaction volume) (39). The GST reaction was monitored at 340 nm and the spontaneous non-enzymatic slope was subtracted from the total observed slope. The extinction coefficient for CDNB was 9600 M⁻¹ cm⁻¹. The LDH reaction was monitored at 340 nm and the extinction coefficient for NADH was 6219 M⁻¹ cm⁻¹. The GST assay consisted of 3.3 mM pyruvate, 0.34 mM NADH, and 100 μg/mL protein in PBS at 37°C (final concentrations in 150 μL reaction volume) (40). The LDH reaction was monitored at 340 nm and the spontaneous non-enzymatic slope was subtracted from the total observed slope. Purified LDH enzyme standards were used to ensure that values were obtained within the linear range of the assay. The extinction coefficient for NADH was 6219 M⁻¹ cm⁻¹. Protein concentration was determined using the bicinchoninic acid method according to the manufacturer’s protocol (Pierce).

**Stereotaxic Injections:** Rats were anaesthetized by i.p. injection of Somnitol (MTC Pharmaceuticals, Cambridge, ON) and placed in a stereotaxic frame (David Kopf Instruments). A burr hole was drilled and injection was performed into the right striatum at coordinates: +1.00 mm anterior-posterior from Bregma, 2.6 mm medial-lateral, and both 4.5 & 5.5 mm dorsal-ventral, using a 10 μl Hamilton gas-tight syringe with 26 gauge needle (type 2 tip). The virus was delivered by manually pressing the syringe plunger 3 times at 4 min intervals. Ad-GFP or Ad-Nrf2 was delivered at a concentration of 5 x 10⁹ total plaque forming units in 3 μl of PBS. Wounds were irrigated with 0.9% sterile saline solution and sutured. Animals were allowed to recover for 3 days before 3-NP treatment was initiated.

**Immunohistochemistry:** For rats, frozen 10 μm brain sections were thawed in PBS for 3 min at room temperature (RT). Mouse monoclonal anti-O4 (Chemicon) or rabbit polyclonal anti-GFAP antibodies were diluted 1:400 and 1:200 respectively in Ab buffer (3% BSA and 0.3% Triton X-100 in PBS) and incubated overnight at 4°C in a humid chamber. Sections were rinsed 3 x 5 min in PBS and incubated with goat anti-mouse IgM Alexa546 conjugated or goat anti-rabbit Alexa546 conjugated secondary antibodies (both Molecular Probes, 1:500) in a humid chamber for 1 h at RT. Sections were rinsed 3 x 10 min in PBS prior to mounting with Fluormount-G (Southern Biotechnology Associates Inc.) and No.1 glass coverslips (Corning). All GFP fluorescence from viral infection could be detected without using an anti-GFP antibody. To assess total striatal volume, a propidium iodide (PI) counterstain was used to label all cell nuclei. Sections were incubated in 8 μM PI dissolved in PBS for 10 min at RT followed by a 10 min PBS rinse. To determine infectivity, GFP fluorescence was calculated by thresholding images to subtract background and calculating the area of fluorescence (ImageJ). In the same section, PI staining was used to locate the corpus callosum and caudate putamen. The area encompassed by these two regions was defined as the striatal area. Data was expressed as % GFP⁺ volume within the total striatal volume. For NeuN staining, an antigen retrieval process was used following thawing. Sections were incubated at 80°C for 30 min in 10 mM sodium citrate pH 8.5 and then rinsed for 5 min in PBS prior to anti-NeuN antibody incubation overnight at 4°C (Chemicon, 1:100) and goat anti-mouse Cy3 secondary antibodies for 1 h at RT (Sigma, 1:200). Fluorescent images were captured using a Zeiss LSM Meta 510 confocal microscope and analyzed using NIH Image (for Mac) or ImageJ (for PC).

**Preparation of primary glial-enriched and COS-1 cultures:** Enriched glial cultures were prepared from 0-2 d post-natal Wistar rat pups as described previously (6). The conditions used largely results in a population of Type I and II astrocytes as assessed by anti-glia- fibrillary acid protein (GFAP) staining. COS-1 cells (ATCC) were maintained in DMEM supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, 2 mM glutamine, 100 U/mL penicillin, and 0.1 mg/mL streptomycin.

**Plasmids and Adenoviruses:** PEF mammalian expression plasmids carrying cDNA encoding mouse Nr2f2 and Nr2f2DN were a generous gift from Dr. Jawed Alam (Alton Ochsner Medical Foundation, New Orleans, LA) (1). Rat ARE sequences were obtained from the NQO1 promotor. The human placental alkaline phosphatase (hPAP) reporter plasmid (rQR51) was constructed as described previously (6,41). Recombinant adenoviral vectors were generated using the Cre-lox system (Canadian
Stroke Network core facility, University of Ottawa), as described previously (6,42). The N-terminus-tagged Nrf2-GFP vector was made by PCR-amplifying the Nrf2 coding sequence from the PEF vector with specific primer sequences: forward, 5'—ACTCAGATCTCGAGAAGATTTGATTGACATCCTT-3’ and reverse, 5’—CCCGGGGGTACCCTAGTTTTTCTTTGTATC-3’. The resulting PCR product was restriction digested with Xho I and Kpn I for ligation into the pEGFP-N1 vector (Invitrogen). The Keap1 vector was a generous gift from Dr. Masayuki Yamamoto (University of Tsukuba), later modified to Keap1-FLAG by Laurie Zipper (University of Wisconsin) (9,43).

Transfection, infection, and treatments for astrocytes and COS-1 cells: Astrocytes and COS-1 cells seeded (1 x 10^5 cells/mL) in 24-well plates were transfected using Lipofectamine 2000 (Invitrogen), according to the manufacturer’s protocol with some modifications. In particular, for each well of a 24-well plate, 1 µg of DNA and 1 µL of lipofectamine were used. The transfection efficiency was typically ~ 20% for astrocytes and ~ 50% for COS-1 cells as assessed by β-galactosidase staining. For some experiments, adenovirus infection of astrocytes as described previously (6), was initiated immediately after lipofectamine transfection. All infected cultures were examined for adequate infection efficiency (~90 % of glia) as assessed by GFP fluorescence. 3-NP or tBHQ treatments were initiated 24 h after transfection.

3-NP was prepared in basic salt solution (BSS) consisting of (in mM) 3.1 KCl, 134 NaCl, 2.5 CaCl2, 1 MgSO4, 0.25 KH2PO4, 15.7 NaHCO3 (pH 7.2), and filtered before use. The 3-NP stock was further diluted in BSS to the indicated concentration for experiments. Cells were washed with BSS twice and then exposed to 3-NP or BSS (vehicle) for 2 h. The cells were washed again 3 times with BSS and the original culture media was replaced. The Nrf2 inducer, tBHQ, was dissolved as a 1000x concentrated stock in pure DMSO (vehicle), sterile filtered, and then diluted to a final concentration of 10 or 20 µM in the glial culture media. TPHQ was present in the media for the duration of the experiment until cells were harvested.

Placental alkaline phosphatase assay: Human placental alkaline phosphatase (hPAP) activity was measured as described previously (44). Briefly, cultures were collected in lysis buffer consisting of 10 mM Tris-HCl (pH 8), 1 mM MgCl2, and 0.1% Triton X-100. Half of the sample was saved for determination of protein concentration and β-galactosidase activity (for normalization of transfection efficiency). The remaining sample was heated to 65°C for 30 min to inactivate endogenous phosphatase activity. The assay was initiated by mixing ~15 µg protein with diethanolamine buffer (0.73 M diethanolamine with 0.36 mM MgCl2, pH 9.8), and 13.6 mM p-nitrophenyl phosphate (final concentrations in 150µL reaction volume). The reaction was monitored every 2 min over 30 min, at 405 nm. For all assays, hPAP activity from rQR51mut transfected astrocytes were subtracted as ARE-independent background.

Semi-qualitative reverse-transcriptase PCR: Total RNA was isolated from infected cultures using Trizol Reagent (Life Technologies, GIBCO) following manufacturer’s instructions. One µg of RNA was reverse transcribed using random hexamer primers and Thermoscript reverse transcriptase enzyme (Invitrogen). The resulting cDNA was then amplified by PCR using various primer sets (31):

Mouse Nrf2 exon 5, 5’—TCTCCTCGCTGGAAAAAGAA-3’ and 5’—AATGTGCTGGCTGTGCTTTA-3’;
NQO1, 5’—CATTCTGAAAGGCTGGTTTGA-3’ and 5’—CTAGCTTTGATCTGGTTGTCAG-3’;
xCT, 5’—TTGCAAGCTCAGCAGCAATT-3’ and 5’—CGTCAGAGGATGCAAAACAA-3’;
GCLC, 5’—ACAAGCACCCCCGCTTCGGT-3’ and 5’—CTCCAGGCCTCTCTCCTCCC-3’;
β-actin, 5’—CCCA GCA GCA GAG GTA TC-3’ and 5’—AGA GCA TAG CCC TCG TAG AT-3’.

PCR conditions were as follows: initial denaturing step using 1 cycle at 95°C for 3 min, followed by 26 cycles at 95°C for 30 s, the appropriate primer annealing temperature (~55°C) for 40 s, 72°C for 1 min, and a final cycle at 72°C for 5 min. For xCT and GCLC, 36 and 31 cycles were used, respectively. The PCR products were separated on a 1.4% agarose gel containing ethidium bromide. cDNA was then visualized using an ultraviolet light source. cDNA templates for each sample were serially diluted and band densities were plotted. These plots were used to ensure that data represented PCR products within the linear range of the reaction (Suppl. Fig. 2).

Glutathione assay: Total glutathione was quantified in glial cell lysates and tissue homogenates (0.3 mg/mL) by the method of Tietze (45), as described previously (6).

Western Blot Analysis and Immunocytochemistry: Western blot and immunocytochemistry was performed as described previously (6). Antibodies used include: rabbit anti-heme oxygenase 1

Downloaded from http://www.jbc.org/ by guest on July 10, 2020
Nrf2-/- mice and then assessed what impact these had regimes that would provide significant impairment in increasing doses of 3-NP (given 12 h apart). Nrf2-/- before 3-NP treatment. However, with progressively metabolic inhibition system impairment and toxicity attributed to examine how loss of Nrf2 function affects both motor treatment of 3-NP toxicity progression. Repeatedly on the same animals providing a measure adjunct to histology is that it can be performed advantage of using behavioral assessment as an restricted to the dorso-lateral striata (33). An activity, hind limb and truncal dystonia, and postural motor symptoms (i.e. reduced general locomotor was monitored through both manifestation of overt symptoms (i.e. reduced general locomotor activity, hind limb and truncal dystonia, and postural instability) and development of bilateral lesions restricted to the dorso-lateral striata (33). An advantage of using behavioral assessment as an adjunct to histology is that it can be performed repeatedly on the same animals providing a measure of 3-NP toxicity progression.

In assays of motor behavior Nrf2+/− mice were indistinguishable from Nrf2+/+ and Nrf2+/− controls before 3-NP treatment. However, with progressively increasing doses of 3-NP (given 12 h apart), Nrf2+/− mice exhibited motor deficits more quickly than controls (Fig. 1A). This increased sensitivity of Nrf2+/− mice became obvious after the 9th scheduled injection (60 mg/kg dose). 3-NP administration was ceased at this point due to increased morbidity of Nrf2+/− mice. Preceding motor deficits, Nrf2+/− mice also began to lose significant amounts of weight separating them from control groups (Fig. 1B). By the end of the experiment, Nrf2+/− mice lost nearly 20% of their body weight. Consistent with behavioural scores, the doses given were insufficient to produce striatal lesions in Nrf2+/+ mice. However, the majority of 3-NP challenged Nrf2+/− mice exhibited extensive striatal lesioning (Fig. 1C,D left column, and 1E). Nrf2+/− mice also developed striatal lesions that, on average, were ~7-fold smaller than in Nrf2+/− mice (lesion volumes, +/- = 0.00 ± 0.00 mm3, +/- = 0.74 ± 0.41 mm3, +/- = 5.24 ± 1.50 mm3, uncorrected for edema). Both motor deficits and weight loss were highly correlated with lesion size during 3-NP treatment (Suppl. Fig. 1) (46). In addition, edema was likely contributing to the pathology of these mice since the striatal volume of 3-NP treated Nrf2+/− mice was ~27% larger than controls (total striatal volume, +/- = 7.95 ± 0.54 mm3, +/- = 7.98 ± 0.29 mm3, +/- = 10.14 ± 1.19 mm3, * p < 0.05).

Lesions of Nrf2+/− mice contained mainly pyknotic cells which stained positive for fluorojade, a marker of neuronal degeneration (Fig. 1D center and right column, and 1F) (34). Only a sub-population of the remaining neurons in the Nrf2+/− lesions was fluorojade-positive, and little or no positive cells were observed in the striata of Nrf2+/+ mice. No significant extra-striatal (i.e. hippocampal or cortical) fluorojade-positive staining was observed in 3-NP treated Nrf2+/− mice, consistent with the striatal-specific action of systemic 3-NP administration. Importantly, Nrf2+/− mice were specifically sensitive to 3-NP since injection of PBS control solution caused negligible motor abnormalities and no lesions/fluorojade-positive neurodegeneration (data not shown). Although the treatment regimen we used did not cause toxicity in Nrf2+/+ mice, prolonged 3-NP administration (1–2 doses of 60 mg/kg 3-NP beyond current regimen) was able to provoke the development of motor deficits and lesions (data not shown).

Striatal SDH Inhibition by 3-NP is Not Different Among Genotypes

Since we used systemic administration of 3-NP, it was possible that increased toxicity in Nrf2+/− mice was due to compromised peripheral detoxification systems (i.e. liver, kidney, and
intestines), leading to a higher circulating concentration of 3-NP in the brain. To address this possibility, we directly quantified SDH activity in the brain after an acute systemic injection of 3-NP (60 mg/kg). The cortex and striatum were collected after 2 h when peak brain SDH inhibition was shown to occur (47). SDH activity was reduced by 40-50% in total tissue from cortex and striatum of all genotypes, consistent with previous studies (Fig. 2)(47). Importantly, we observed no difference in SDH activity between genotypes, suggesting that increased damage caused by 3-NP in Nrf2-/- mice is most likely due to an intrinsic sensitivity in their brains.

**Pre-activation of Nrf2 by tert-butylhydroquinone attenuates 3-NP toxicity in Nrf2+/-, but not Nrf2-/- mice.**

Nrf2 induction by small electrophilic molecules represents a practical method to increase the Phase 2 response *in vivo* (48-50). Dietary administration of Nrf2 inducers, such as sulforaphane (isolated from broccoli sprouts) have been shown to induce Phase 2 genes in peripheral tissues and reduce toxicity associated with a number of pathologies, including stomach tumour formation and hypertension (18,51). To determine whether *in vivo* induction of Nrf2 could provide resistance to 3-NP toxicity, mouse diets were supplemented with the potent Nrf2 inducer, tert-butylhydroquinone (tBHQ) (1,52).

The *in vivo* phase 2 response was assessed by measuring the activities of two prototypic phase 2 enzymes, glutathione S-transferase (GST) and NAD(P)H:quinone oxidoreductase (NQO1), as well as total glutathione (GSH) content. Nrf2-/- mice exhibited lower basal striatal and cortical activity for GST and NQO1, when compared to Nrf2+/- littermate controls (Table 1, basal phase 2 enzyme levels). Interestingly, basal brain GSH levels were not altered, suggesting constitutive synthesis of brain GSH does not rely on Nrf2 function, at least in the young adult mice examined in here. As observed in previous studies, GST, NQO1 activities, and total GSH levels were markedly reduced in the livers of Nrf2-/- mice (53-56). The housekeeping gene, lactate dehydrogenase (LDH), is not regulated by Nrf2 and accordingly, no significant differences in activity were observed between genotypes.

Primarily Nrf2+/- and Nrf2-/- mice were used in tBHQ feeding studies since we were interested in observing reduced motor deficit and lesion size during 3-NP treatment, and Nrf2+/- mice did not develop these phenotypes. The tBHQ-supplemented diet (1% w/w) was well tolerated by Nrf2+/- mice since no significant weight loss was observed over 1 week of feeding, except a transient loss of weight 2 d after initiation of feeding, and food consumption was similar with mice receiving control diet (Fig 3A,C). However, Nrf2+/- mice were less tolerant of dietary tBHQ with overall body weight ~ 10-20% lower than mice with control diet during 1 week of feeding (Fig. 3B, *** p < 0.0001 2-way ANOVA), and less food consumption than tBHQ-fed Nrf2-/- mice (Fig. 3B,D). In total, Nrf2+/-, and Nrf2-/- mice consumed 12.9 ± 0.9, and 7.6 ± 0.7 mg tBHQ/g body weight over 1 week, respectively. The 1% tBHQ diet increased striatal and cortical GSH levels in Nrf2-expressing mice (Nrf2+/- and Nrf2+/-)(Table 1, tBHQ-induced phase 2 enzyme levels). Importantly, the induction of brain GSH was not observed in Nrf2-/- mice, providing evidence that tBHQ-induced changes in GSH are Nrf2 dependent. In addition, tBHQ-induced increase in liver GST and NQO1 activities was observed in Nrf2 expressing mice, but not Nrf2-/- mice, consistent with the effects of other Nrf2 inducers used *in vivo* (56,57). However, no induction of GST or NQO1 was detected in brain. Levels of the negative control enzyme, LDH, was unaffected by tBHQ in all tissues examined. Interestingly, we observed an increase in liver GSH levels in tBHQ-fed Nrf2-/- mice. We believe that this Nrf2-independent change may reflect an inherent hepatic toxicity associated with tBHQ feeding, perhaps due to inefficient detoxification from the body by the same pathways regulated by Nrf2 (Phase 2 genes). Together, these results highlight the sensitivity of the Nrf2+/- phenotype to tBHQ toxicity and suggest normal Phase 2 induction in response to tBHQ is abrogated in Nrf2-/- mice.

The tBHQ diet was given 1 week prior to the 3-NP regimen and maintained until sacrifice. TBBHQ-fed Nrf2+/- mice had significantly attenuated 3-NP induced motor deficits compared to mice receiving the control diet (Fig. 3E, ** p < 0.001 two-way ANOVA). In contrast, tBHQ-fed Nrf2-/- mice exhibited an overall exacerbation of motor deficit (Fig. 3F, *** p = 0.0002 two-way ANOVA). The average lesion volume of Nrf2+/- given control diet was similar to that measure in our initial experiments (0.65 ± 0.29 mm³, uncorrected for edema) (Fig. 3G,H). However, consistent with reduced behavioural scores, no tBHQ-fed Nrf2+/- mice exhibited detectable lesions indicating protection of neurons. TBBHQ feeding did not reduce lesion size in Nrf2-/- mice, confirming the protective effect of tBHQ consumption was Nrf2-dependent (Fig. 3G,H).
Adenoviral overexpression of Nrf2 attenuates 3-NP induced striatal lesioning in vivo.

To further address whether activation of Nrf2-dependent pathways is sufficient to protect the striatum during 3-NP toxicity, in parallel studies, we tested whether direct Nrf2 overexpression using adenovirus vectors (Ad-Nrf2 or Ad-GFP control) conferred neuroprotection to rats treated with 3-NP. Overexpression of Nrf2 causes its accumulation in the nucleus leading to even more robust ARE-dependent transcription than that observed with small molecule inducer treatment (43). In vivo intrastriatal adenovirus injection primarily led to infection of astrocytes (Fig. 4A top panel, and 4B), and almost no neurons or oligodendrocytes (Fig. 4A middle and bottom panel, and 4B). Vector diffusion was observed throughout the striatum (Fig. 4C), infecting 0.48 ± 0.08% of the total striatal volume, as assessed by the presence of the GFP marker (Fig. 4D). After infection, protein expression was allowed to occur for 3 days before 3-NP treatment was initiated.

Following 3-NP challenge, lesion volumes in the infected hemisphere were significantly smaller in animals receiving Ad-Nrf2, compared to Ad-GFP control virus (9.6 ± 2.6 mm³ versus 23.4 ± 4.2 mm³, p = 0.03, two-tailed t-test, Fig. 4E,F). Interestingly, a trend toward decreased lesion volume was also observed in the hemisphere contralateral to the virus injection (12.2 ± 3.8 mm³ compared to 25.9 ± 4.9 mm³, p = 0.06), although this difference did not attain statistical significance. This effect is likely due to diffusion of secreted glial factors, possibly glutathione or glutathione precursors, by volume transmission along fiber bundles of the corpus callosum, or through the cerebral spinal fluid from the infected Nrf2 overexpressing astrocytes in the ipsilateral hemisphere (58,59).

3-NP activates ARE-dependent gene expression in cultured astrocytes.

Our data show that both the Nrf2 inducer tBHQ and Nrf2 overexpression could protect neurons by pre-activating the Phase 2 response. Since increased susceptibility of Nrf2⁻/⁻ mice may result from inability to activate expression of protective genes necessary for reducing toxicity associated with 3-NP, we hypothesized that metabolic inhibition by 3-NP was acting as a signal for Nrf2 activation. To test this hypothesis, we examined the effect of 3-NP on Nrf2 activity in cultured astrocytes, the primary site of ARE-mediated gene expression in brain cultures (6,41,60).

To mimic the effects of bolus in vivo injection, cultured astrocytes were treated with a wide range of 3-NP concentrations (1-30 mM) for 2 h and then ARE-mediated gene expression was assessed using a hPAP reporter assay regulated by an ARE-bearing NQO1 promoter 24 h later (Fig. 5A) (41). Astrocytes transiently treated (2 h) with 10-30 mM 3-NP exhibited a doubling of ARE-mediated gene expression. Over these time periods and with these 3-NP concentrations no apparent astrocyte toxicity was observed. Expression of ARE-driven hPAP, with and without 3-NP exposure, was reduced to sub-basal levels when astrocytes were infected with adenovirus overexpressing a dominant-negative form of Nrf2 (Ad-Nrf2DN), but not with overexpression of GFP control (Ad-GFP) (Fig. 5B) (6). Exposure to tBHQ (20 μM for 24 h) induced hPAP expression to a similar extent as 3-NP treatment. Maximal hPAP activity was achieved with Nrf2 overexpression (Ad-Nrf2). Although the concentrations of 3-NP we use to activate Nrf2 mediated gene expression are high, the ability of dominant negative Nrf2 to block the induction indicates that it is nonetheless mediated by the ARE. Perhaps these high concentrations reflect the activated and toxin-resistant nature of astrocytes in vitro (61).

Semi-quantitative RT-PCR confirmed that astrocytes treated with 30 mM 3-NP for 2 h expressed higher levels of prototypic Nrf2 target gene mRNAs including NQO1, γ-glutamylcysteine synthetase (GCLC), and the cysteine/glutamate exchanger (xCT) (Fig 5C). The expression of these mRNAs was increased by Ad-Nrf2 and suppressed by Ad-Nrf2DN infection, verifying the specificity of these target genes. For all RT-PCR experiments, DNA templates were serially diluted to ensure that band intensities were observed within the linear range of the PCR reaction (Suppl. Fig. 2). Since a number of Nrf2 target genes are involved in GSH synthesis (i.e. xCT, GCLC, and glutathione synthase), treatment with 30 mM 3-NP also increased intracellular GSH levels in cultured astrocytes (Fig. 5D) (5,6,54,55). Consistent with ARE-driven hPAP expression, 3-NP-mediated GSH induction was blocked with Ad-Nrf2DN infection, but not Ad-GFP control (Fig. 5D). Protein levels of heme oxygenase-1 (HO-1), a well characterized Nrf2 target, were also induced by 3-NP treatment (Fig. 5E,F). Consistent with the GSH data both basal and induced expression of HO-1 was suppressed with Ad-Nrf2DN infection. Although this analysis does not encompass the full scope of Nrf2 gene targets, it nevertheless indicates...
the Phase 2 response is activated as a dose-dependent effect of 3-NP.

We further evaluated nuclear translocation of GFP-tagged Nrf2 (Nrf2-GFP) in response to 3-NP exposure. In initial experiments using astrocytes, Nrf2-GFP fluorescence was almost undetectable when co-expressed with its cytoplasmic regulator Keap1, possibly due to a faster rate of Nrf2 turnover by proteasome dependent pathways (62). As an alternative, COS-1 cells were used because of their high level of trans-gene expression and well-defined morphology for evaluating nuclear versus cytoplasmic localization. Consistent with previous studies, overexpressed Nrf2-GFP was almost exclusively localized to the nucleus unless co-expressed with Keap1 (Keap1-FLAG) (Fig. 6A, top row) (13,43). COS-1 cells co-expressing Nrf2-GFP and Keap1-FLAG were evaluated after treatment with 3-NP or BSS vehicle control for 2 h. As expected, the proportion of cells exhibiting nucleus-enriched Nrf2-GFP fluorescence was significantly higher in 3-NP-treated cultures, when compared to vehicle control (Fig. 6A,B). Interestingly, 3-NP treatment also caused some aggregation of Keap1 and Nrf2-GFP in the cytoplasm, which we speculate is due to 3-NP-induced endoplasmic reticulum stress causing accumulation of unfolded proteins (63). This effect was transient since the aggregations were not observed 24 h after 3-NP washout (data not shown). Treatment with 20 μM tBHQ for 4 h, as a positive control, also robustly increased nuclear localization of Nrf2-GFP (Fig. 6A,B). Both Nrf2-GFP and Keap1-FLAG constructs were functional, as assessed by their ability to augment and suppress ARE-driven hPAP expression, respectively (Fig. 6C).

Collectively, this in vitro data confirms Nrf2 translocates to the nucleus and initiates Phase 2 genes induction in response to 3-NP mediated metabolic inhibition. This effect can be mimicked using the Nrf2 inducer, tBHQ, and by adenoviral Nrf2 overexpression.

Discussion

This study provides evidence to support the neuroprotective function of Nrf2 during metabolic compromise in the in vivo brain. First, loss of Nrf2 function led to an increased susceptibility to 3-NP since Nrf2−/− mice developed motor deficits and striatal lesions more rapidly than Nrf2 expressing controls. Second, pre-activation of endogenous Nrf2 using the small molecule inducer, tBHQ, attenuated 3-NP toxicity in Nrf2−/− mice, but not Nrf2+/−, confirming both the neuroprotective action and Nrf2-dependedence of tBHQ in vivo. Third, direct overexpression of tBHQ in vivo. Third, direct overexpression of Nrf2 in the striatum is sufficient to reduce lesion size caused by 3-NP. Fourth, ARE-dependent gene expression in cultured astrocytes was activated by 3-NP, and could be completely suppressed by overexpression of a dominant-negative form of Nrf2.

Nrf2−/− mice are hypersensitive to 3-NP toxicity.

The increased sensitivity of Nrf2−/− mice may result from an inability to induce Phase 2 genes in response to 3-NP toxicity. Indeed, a recent study by Calkins et al. (published while this work was submitted) showed using transgenic reporter mice, that ARE-dependent gene expression occurred in the immediate border of 3-NP induced striatal lesions, perhaps in reactive astrocytes commonly found within this region (64). Since Nrf2 is generally thought to respond to oxidative stress or signal transduction pathways associated with it (65,66), we speculate that 3-NP activates this protective pathway by indirectly generating ROS/RNS. 3-NP may increase brain oxidative stress through multiple mechanisms that may be implicated in our in vitro and in vivo experiments (6,29-31). Also supported by our data, an alternative possibility for the increased sensitivity of Nrf2−/− mice may be the lower basal levels of phase 2 enzymes expressed in this genotype (Table 1, basal phase 2 enzyme levels) (83).

Given that systemic 3-NP undergoes first pass metabolism before it reaches the striatum, it was possible that increased striatal damage in Nrf2−/− mice was in part due to impaired clearance of 3-NP from the body by peripheral detoxification. Indeed previous studies of Nrf2−/− mice have shown decreased Phase 2 enzyme activity in the liver and intestines (53,67), organs which may affect the removal of systemically injected 3-NP. However, we have shown that after a single high in vivo dose of 3-NP, striatal SDH was inhibited to an equal extent between Nrf2+/+ and Nrf2−/− genotypes, suggesting that 3-NP produces similar metabolic inhibition on a dose-wise basis regardless of genotype. Thus, it appears that the brains of Nrf2−/− mice are intrinsically more sensitive to direct damage. This conclusion is also supported by a number of other findings. First, neurons and glia isolated from Nrf2−/− mice are more sensitive to in vitro toxicity paradigms involving oxidative stress or metabolic compromise (8,28,31). Second, direct injection of malonate (reversible SDH inhibitor) into the striatum produced larger lesions in Nrf2−/− mice, compared to Nrf2 expressing controls (64). Third, Nrf2−/− mice develop larger cortical...
infarcts than Nrf2 +/- mice after experimental stroke (permanent distal middle cerebral artery occlusion), a model which also involves local brain metabolic inhibition (unpublished data)(84).

The small molecule inducer, tBHQ, provided Nrf2-dependent amelioration of 3-NP toxicity in vivo.

Although studies indicate that loss of Nrf2 potentiates neurotoxicity (64), whether the in vivo effects of small molecule inducers of ARE-mediated gene expression are lost in Nrf2 knockout mice has not been previously addressed. In support of a neuroprotective role for Nrf2 in vivo, pre-activation of Nrf2 by the small molecule, tBHQ was capable of attenuating 3-NP toxicity. Previous in vitro studies have shown that tBHQ exposure augments ARE-dependent gene expression in cultured astrocytes and protects neurons from toxicity paradigms involving oxidative stress (6,28,68,69). We extend these findings to the in vivo situation since dietary consumption of tBHQ significantly reduced motor deficits and lesion developments in Nrf2 +/- mice. Importantly, the protective effect of tBHQ was abrogated in Nrf2 +/- mice. Furthermore, dietary tBHQ administration increased brain GSH levels in Nrf2 +/- and Nrf2 +/- mice, but not Nrf2 +/- mice (Table 1, tBHQ-induced phase 2 enzyme levels).

As expected from previous studies (70), dietary tBHQ treatment also increased Phase 2 enzyme activity (GST and NQO1) in the liver. Thus, it remains possible that attenuation of 3-NP toxicity in tBHQ-fed mice could be in part due to enhanced removal of 3-NP from the body by increased liver detoxification or conceivably liver derived antioxidants such as GSH released into the blood. However, our observed increase in brain GSH would be expected to contribute to local neutralization of ROS/RNS, leading to tissue preservation. In preliminary studies, we have found that even local infusion of tBHQ in brain ventricles using osmotic pumps can lead to increases in liver phase 2 enzyme levels suggesting that it is difficult to completely dissociate brain and peripheral organ detoxification. Future studies could more directly address the role of brain Nrf2 by developing tissue and organ specific Nrf2 knockouts. However, in support of the brain being the site of tBHQ action, overexpression of Nrf2 within the striatum using adenovirus was sufficient to reduce the effect of systemically administered 3-NP. Although some uncertainty remains as to the site of Nrf2 induction mediated by tBHQ in vivo, our study nonetheless indicates that striatal-specific damage due to the systemic administration of a metabolic stressor can be strongly attenuated by this dietary strategy. Given that many neurodegenerative diseases may be triggered by exposure to diet or lung-derived toxins (71-73), it is conceivable that a dietary strategy to increase antioxidant function in multiple organs may be an ideal prophylactic strategy. To our knowledge, this is the first study to show that a protective effect of a Phase 2 inducer on brain function in vivo is dependent on Nrf2.

Although tBHQ is widely used as a food antioxidant, and is well-tolerated by the body (74,75), it is also important to consider the detrimental action of tBHQ and other Nrf2 inducers. As observed in this study Nrf2 +/- mice do not tolerate tBHQ administration as well as controls (as evidenced by weight loss and reduced food consumption) perhaps due to inefficient detoxification of tBHQ through Nrf2-regulated pathways (Fig. 3A,B). Other groups have also found that Nrf2 +/- mice are less tolerant to dietary administration of known Nrf2 inducers (67). Recently, increased susceptibility to hypoxia has been linked to polymorphisms in the Nrf2 gene (76). The question arises as to whether such mutations affect Nrf2 function in humans, and could underlie sensitivity to human disease. Since many Nrf2 inducers are essentially reactive electrophiles, the inability to properly detoxify Nrf2 inducers from the body could be harmful to individuals with such a genetic predisposition.

With regard to practical application, recent studies have elucidated a variety of structurally related small molecules which are able to activate Nrf2 by reacting with thiol/disulfide groups on the cytoplasmic regulatory protein Keap1 (4,48,50,77-79). Some of these inducers are found within our diet. For example, the isothiocyanate sulforaphane, a potent Nrf2 inducer abundant in cruciferous plants (i.e. broccoli sprouts), was found to inhibit gastric tumour formation in mice by administration of benzo[a]pyrene (78). Juurlink and colleagues have recently demonstrated a significant improvement of cardiovascular fitness in spontaneously hypertensive rats through chronic upregulation of Phase 2 enzymes by supplementing diets with broccoli sprouts (51,80). Such studies support the potential for mitigating oxidative tissue damage in chronic disorders involving oxidative stress, by applying a change in diet -a practical and realistic therapeutic approach from a clinical standpoint.

Overexpression of Nrf2 protein is sufficient to provide neuroprotection in vivo.
We have also conducted a proof of principle experiment showing that adenoviral overexpression of Nrf2 in the striatum is sufficient to reduce 3-NP toxicity in vivo. Adenovirus was found to mainly infect astrocytes throughout the striatum as well as in the corpus callosum. In our immunohistochemical analysis, we observed that some GFP-positive cells with astrocyte morphology (~35%) were not labeled by any cell-type marker tested. However, these cells were labeled by a different astrocyte marker, S100β (total GFP and S100β co-localization = 91.8 ± 0.2%, n = 2), confirming their identity (81). With regard to the extent of neuroprotection achieved with Nrf2 overexpression in vivo, we have previously demonstrated a small number of Ad-Nrf2 infected astrocytes can confer protection to many neighbouring neurons during an oxidative glutamate insult in vitro (1 astrocyte can protect 100 neurons) (6). These Nrf2 overexpressing astrocytes secrete high levels of glutathione, providing a means for a small number of astrocytes to affect the survival of a much larger number of neurons (6). In support of our findings, Calkins et al. observed significant neuroprotection in vivo by transplanting a relatively small number of Nrf2 overexpressing astrocytes (from culture) directly into the striatum prior to injection of the competitive complex II inhibitor, malonate (64). In addition, many factors contributing to oxidative stress (i.e. ROS/RNS) are cell permeable allowing them to be metabolized in a subpopulation of cells (82). Another factor to consider is the actual spatial localization of the astrocytes infected in situ. The patchy nature of the infection (Fig. 4C) suggests a wider area can be protected within the volume of the brain. Furthermore, there is precedent for a small number of cells playing a major role in striatal function. One such example are the cholinergic interneurons of the striatum which only make up 1-2% of all striatal neurons yet have profound impact on the functional output of the striatum influencing such diverse behaviours as sensorimotor function, sleep & arousal states, learning & memory, anxiety and pain sensations (83).

3-NP exposure activated ARE-mediated gene expression in vitro.

Our in vitro experiments show that 3-NP exposure upregulated Phase 2 gene expression in cultured astrocytes, providing a mechanistic link between 3-NP and Nrf2 activation. The effect of 3-NP was attributed to Nrf2 since a dominant negative version of Nrf2 was able to block the effect of 3-NP. However, further experiments are necessary to determine which component of 3-NP toxicity acts as a signal for Nrf2 activation. For example, Nrf2 activation may result from 3-NP induced ROS/RNS generation, loss of ATP, or even as a direct response to SDH inhibition. In preliminary studies using cultured astrocytes, we examined the level of SDH inhibition caused by the range of 3-NP concentrations used in vitro. After 2 h of exposure to non-Nrf2 inducing 3-NP concentrations (0.3-1 mM), SDH activity was reduced by ~ 90%. However, at Nrf2 inducing concentrations (10-30 mM), SDH activity was almost completely inhibited (~ 98%). Given this difference, it is possible that a non-linear relationship exists between SDH activity and activation of ARE-mediated gene expression. Conceivably, the requirement for high concentrations of 3-NP to induce Nrf2 mediated gene expression may in part be due the high intrinsic resistance of cultured astrocytes which show an activated phenotype to agents that induce metabolic inhibition and oxidative stress (61).

Conclusion.

Nrf2 plays an important role in regulating neuronal survival during metabolic compromise in vivo. The absence of Nrf2 function in Nrf2−/− mice exacerbates neurodegeneration caused by 3-NP administration. Augmentation of ARE-mediated gene expression in Nrf2-expressing animals using the small molecule inducer, tBHQ, attenuated tissue damage and preserved motor function. Dietary administration of Nrf2 inducers may have profound effects for neuronal viability in neurodegenerative disease, stroke and other related forms of energy deprivation.

References

1. Alam, J., Stewart, D., Touchard, C., Boinapally, S., Choi, A. M., and Cook, J. L. (1999) J Biol Chem 274, 26071-26078.
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., Yamamoto, M., and Nabeshima, Y. (1997) *Biochem Biophys Res Commun* **236**, 313-322.

2. Rushmore, T. H., Morton, M. R., and Pickett, C. B. (1991) *J Biol Chem* **266**, 11632-11639.

3. Ishii, T., Itoh, K., Takahashi, S., Sato, H., Yanagawa, T., Katoh, Y., Bannai, S., and Yamamoto, M. (2000) *J Biol Chem* **275**, 16023-16029.

4. Shih, A. Y., Johnson, D. A., Wong, G., Kraft, A. D., Jiang, L., Erb, H., Johnson, J. A., and Murphy, T. H. (2003) *Journal of Neuroscience* **23**, 3394-3406.

5. Thimmulappa, R. K., Mai, K. H., Srisuma, S., Kensler, T. W., Yamamoto, M., and Biswal, S. (2002) *Cancer Res* **62**, 5196-5203.

6. Lee, J. M., Calkins, M. J., Chan, K., Kan, Y. W., and Johnson, J. A. (2003) *J Biol Chem* **278**, 12029-12038.

7. Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., and Yamamoto, M. (1999) *Genes Dev* **13**, 76-86.

8. Kang, M. I., Kobayashi, A., Wakabayashi, N., Kim, S. G., and Yamamoto, M. (2004) *Proc Natl Acad Sci U S A* **101**, 2046-2051.

9. Chan, K., Han, X. D., and Kan, Y. W. (2001) *Proceedings of the National Academy of Sciences of the United States of America* **98**, 4611-4616.

10. Enomoto, A., Itoh, K., Nagayoshi, E., Haruta, J., Kimura, T., O'Connor, T., Harada, T., and Yamamoto, M. (2001) *Toxicological Sciences* **59**, 169-177.

11. Chan, K., and Kan, Y. W. (1999) *Proc Natl Acad Sci U S A* **96**, 12731-12736.

12. Cho, H. Y., Jedlicka, A. E., Reddy, S. P., Kensler, T. W., Yamamoto, M., Zhang, L. Y., and Kleeberger, S. R. (2002) *Am J Respir Cell Mol Biol* **26**, 175-182.

13. Fahey, J. W., Haristoy, X., Dolan, P. M., Kensler, T. W., Scholtus, I., Stephenson, K. K., Talalay, P., and Lozniewski, A. (2002) *Proceedings of the National Academy of Sciences of the United States of America* **99**, 7610-7615.

14. Ramos-Gomez, M.

15. Coyle, J. T., and Puttfarcken, P. (1993) *Science* **262**, 689-695.

16. Beal, M. F., Brouillet, E., Jenkins, B. G., Ferrante, R. J., Kowall, N. W., Miller, J. M., Storey, E., Srivastava, R., Rosen, B. R., and Hyman, B. T. (1993) *J Neurosci* **13**, 4181-4192.

17. Reynolds, I. J., and Hastings, T. G. (1995) *J Neurosci* **15**, 3318-3327.

18. Schulz, J. B., Matthews, R. T., Jenkins, B. G., Ferrante, R. J., Siwek, D., Henshaw, D. R., Cipolloni, P. B., Mecocci, P., Kowall, N. W., Rosen, B. R., and et al. (1995) *J Neurosci* **15**, 8419-8429.

19. Beal, M. F. (1995) *Ann Neurol* **38**, 357-366.

20. Beal, M. F. (1992) *Ann Neurol* **31**, 119-130.

21. Reynolds, D. S., Carter, R. J., and Morton, A. J. (1998) *J Neurosci* **18**, 10116-10127.

22. Lee, J. M., Shih, A. Y., Murphy, T. H., and Johnson, J. A. (2003) *J Biol Chem* **278**, 37948-37956.

23. Kraft, A. D., Johnson, D. A., and Johnson, J. A. (2004) *Journal of Neuroscience* **24**, 1101-1112.

24. Duffy, S., So, A., and Murphy, T. H. (1998) *J Neurochem* **71**, 69-77.
30. Murphy, T. H., De Long, M. J., and Coyle, J. T. (1991) J Neurochem 56, 990-995
31. Lee, J. M., Shih, A. Y., Murphy, T. H., and Johnson, J. A. (2003) Journal of Biological Chemistry 278, 37948-37956
32. Chan, K., Lu, R., Chang, J. C., and Kan, Y. W. (1996) Proceedings of the National Academy of Sciences of the United States of America 93, 13943-13948
33. Fernagut, P. O., Hervier, L., Labattu, B., Bioulac, B., and Tison, F. (2002) Neuroscience 115, 533-546
34. Schmued, L. C., Albertson, C., and Slikker, W., Jr. (1997) Brain Research 751, 37-46
35. Paxinos, G., and Franklin, K. B. J. (2001) The mouse brain in stereotaxic coordinates, 2nd Ed., Academic, San Diego, Calif. London
36. Paxinos, G., and Watson, C. (1986) The rat brain in stereotaxic coordinates, 2nd Ed., Academic Press, Sydney; Orlando
37. Pennington, R. J. (1961) Biochem J 80, 649-654
38. Benson, A. M., Hunkeler, M. J., and Talalay, P. (1980) Proc Natl Acad Sci U S A 77, 5216-5220
39. Kelly, V. P., Ellis, E. M., Manson, M. M., Chanas, S. A., Moffat, G. J., McLeod, R., Judah, D. J., Neal, G. E., and Hayes, J. D. (2000) Cancer Res 60, 957-969
40. Everse, J., Berger, R. L., and Kaplan, N. O. (1970) Science 168, 1236-1238
41. Murphy, T. H., Yu, J., Ng, R., Johnson, D. A., Shen, H., Honey, C. R., and Johnson, J. A. (2001) J Neurochem 76, 1670-1678.
42. Hardy, S., Kitamura, M., Harris-Stansil, T., Dai, Y., and Phipps, M. L. (1997) J Virol 71, 1842-1849.
43. Zipper, L. M., and Mulcahy, R. T. (2002) J Biol Chem 277, 36544-36552
44. Henthorn, P., Zervos, P., Raducha, M., Harris, H., and Kadesch, T. (1988) Proc Natl Acad Sci U S A 85, 6342-6346
45. Tietze, F. (1969) Anal Biochem 27, 502-522.
46. Guyot, M. C., Hantraye, P., Dolan, R., Palfi, S., Maziere, M., and Brouillet, E. (1997) Neuroscience 79, 45-56
47. Brouillet, E., Guyot, M. C., Mittoux, V., Altairac, S., Conde, F., Palfi, S., and Hantraye, P. (1998) Journal of Neurochemistry 70, 794-805
48. Talalay, P., and Fahey, J. W. (2001) J Nutr 131, 3027S-3033S
49. Talalay, P., Fahey, J. W., Holtzclaw, W. D., Prestera, T., and Zhang, Y. (1995) Toxicol Lett 82-83, 173-179
50. Talalay, P., and Zhang, Y. (1996) Biochim Soc Trans 24, 806-810
51. Wu, L., Ashraf, M. H., Facci, M., Wang, R., Paterson, P. G., Ferrie, A., and Juurlink, B. H. (2004) Proc Natl Acad Sci U S A 101, 7094-7099
52. Nguyen, T., Huang, H. C., and Pickett, C. B. (2000) J Biol Chem 275, 15466-15473.
53. Hayes, J. D., Chanas, S. A., Henderson, C. J., McMahon, M., Sun, C., Moffat, G. J., Wolf, C. R., and Yamamoto, M. (2000) Biochim Soc Trans 28, 33-41.
54. Chanas, S. A., Jiang, Q., McMahon, M., McWalter, G. K., McLellan, L. I., Elcombe, C. R., Henderson, C. J., Wolf, C. R., Moffat, G. J., Itoh, K., Yamamoto, M., and Hayes, J. D. (2002) Biochem J 365, 405-416
55. Chan, J. Y., and Kwon, M. (2000) Biochim Biophys Acta 1517, 19-26.
56. Kwak, M. K., Itoh, K., Yamamoto, M., Sutter, T. R., and Kensler, T. W. (2001) Mol Med 7, 135-145
57. McWalter, G. K., Higgins, L. G., McLellan, L. I., Henderson, C. J., Song, L., Thornalley, P. J., Itoh, K., Yamamoto, M., and Hayes, J. D. (2004) J Nutr 134, 3499S-3506S
58. Bjelke, B., England, R., Nicholson, C., Rice, M. E., Lindberg, J., Zoli, M., Agnati, L. F., and Fuxe, K. (1995) Neuroreport 6, 1005-1009
59. Zoli, M., Jansson, A., Sykova, E., Agnati, L. F., and Fuxe, K. (1999) *Trends Pharmacol Sci* **20**, 142-150

60. Eftekharpour, E., Holmgren, A., and Juurlink, B. H. (2000) *Glia* **31**, 241-248.

61. Olsen, C., Rustad, A., Fonnum, F., Paulsen, R. E., and Hassel, B. (1999) *Brain Res* **850**, 144-149

62. McMahon, M., Itoh, K., Yamamoto, M., and Hayes, J. D. (2003) *J Biol Chem* **278**, 21592-21600

63. Cullinan, S. B., Zhang, D., Hannink, M., Arvisais, E., Kaufman, R. J., and Diehl, J. A. (2003) *Mol Cell Biol* **23**, 7198-7209

64. Calkins, M. J., Jakel, R. J., Johnson, D. A., Chan, K., Kan, Y. W., and Johnson, J. A. (2005) *Proc Natl Acad Sci U S A* **102**, 244-249

65. Nguyen, T., Sherratt, P. J., and Pickett, C. B. (2003) *Annu Rev Pharmacol Toxicol* **43**, 233-260

66. Owuor, E. D., and Kong, A. N. (2000) *Biochem Pharmacol* **64**, 765-770

67. McMahon, M., Itoh, K., Yamamoto, M., Chanas, S. A., Henderson, C. J., McLellan, L. I., Wolf, C. R., Cavin, C., and Hayes, J. D. (2001) *Cancer Res* **61**, 3299-3307

68. Ahlgren-Beckendorf, J. A., Reising, A. M., Schander, M. A., Herdler, J. W., and Johnson, J. A. (1999) *Glia* **25**, 131-142.

69. Johnson, D. A., Andrews, G. K., Xu, W., and Johnson, J. A. (2002) *J Neurochem* **81**, 1233-1241

70. Rahimtula, A. D., Jernstrom, B., Dock, L., and Moldeus, P. (1982) *Br J Cancer* **45**, 935-944

71. Calne, D. B., Eisen, A., McGeer, E., and Spencer, P. (1999) *Lancet* **2**, 1067-1070

72. Di Monte, D. A., Lavasani, M., and Manning-Bog, A. B. (2002) *Neurotoxicology* **23**, 487-502

73. Jenner, P. (2001) *Trends Neurosci* **24**, 245-247

74. FAO/WHO. (1975) *FAO Nutr Meet Rep Ser*, 1-204

75. (1997) *Natl Toxicol Program Tech Rep Ser* **459**, 1-326

76. Cho, H. Y., Jedlicka, A. E., Reddy, S. P., Zhang, L. Y., Kensler, T. W., and Kleeberger, S. R. (2002) *Am J Respir Cell Mol Biol* **26**, 42-51

77. Kensler, T. W., Davidson, N. E., Groopman, J. D., Roebuck, B. D., Prochaska, H. J., and Talalay, P. (1999) *Basic Life Sci* **61**, 127-136

78. Fahey, J. W., Zhang, Y., and Talalay, P. (1997) *Proc Natl Acad Sci U S A* **94**, 10367-10372

79. Fahey, J. W., Zalcmann, A. T., and Talalay, P. (2001) *Phytochemistry* **56**, 5-51

80. Wu, L., and Juurlink, B. H. (2001) *Journal of Hypertension* **19**, 1819-1825

81. Walz, W. (2000) *Glia* **31**, 95-103

82. Drukarch, B., Schepens, E., Stoof, J. C., Langeveld, C. H., and Van Muiswinkel, F. L. (1998) *Free Radic Biol Med* **25**, 217-220

83. Zhou, F. M., Wilson, C. J., and Dani, J. A. (2002) *J Neurobiol* **53**, 590-605

84. Shih AY, Li P, Earl N, Imbeault S, Cheng MN, Gilbert R, Robertson GS, Murphy TH (2004). Program No. 456.13. 2004 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2004. Online

**Footnotes**

We thank Dr. Yuet Wai Kan for Nrf2/-/- mouse production, and Dr. Jeff Johnson for distributing the mice. We also thank the University of British Columbia Animal Care Facility, and Steve Callaghan at the University of Ottawa for production of adenoviruses, and Dr. Alaa El-Husseini for access to the Zeiss Meta confocal microscope. Funded by the Canadian Stroke Network (THM), CIHR (AYS, THM), Heart and Stroke Foundation of BC (THM), Michael Smith Foundation for Health Research (AYS, SI, THM), NSERC (SI), and Rick Hansen Institute (AYS).
The abbreviations used are: Nrf2, NF-E2 related factor; 3-NP, 3-nitropropionic acid; ARE, antioxidant response element; ROS/RNS, reactive oxygen species and reactive nitrogen species; tBHQ, tertiary-butylnhydroquinone; GSH, glutathione; CV, cresyl violet; GFAP, glial fibrillary acidic protein; SDH, succinate dehydrogenase; PI, propidium iodide; hPAP, heat-stable human placental alkaline phosphatase; NQO1, NA(D)PH:quinone oxidoreductase; GST, glutathione S-transferase; GCLC, γ-glutamylecysteine synthetase; xCT, cystine/glutamate exchanger.

Figure Legends

Figure 1. Behavioural scoring, weight loss, and lesions of mice with varied Nrf2 genotype during 3-NP challenge. Behaviour (A) and weight (B) were evaluated before each scheduled injection. The 3-NP treatment regimen consisted of 9 total intraperitoneal injections with one injection given every 12 h at successively increasing doses: 20 mg/kg x 4, 40 mg/kg x 4, 60 mg/kg x 1 (doses are depicted with black bars below the x-axis). At 108 h, behaviour was measured but no injections were made. All animals were sacrificed 1.5 days after the last dose of 3-NP (arrow). (C) Representative Cresyl Violet stained slices from all genotypes after 3-NP treatment. Pallor in staining due to cell death and cell shrinkage is outlined by dotted lines. (D) Representative images from Cresyl Violet stained slices (left column, scale bar = 1 mm), magnified image from Cresyl violet striatal inset (middle column, scale bar = 100 μm), and magnified image of fluorojade staining (marker of neuronal degeneration) from striatal inset (right column, scale bar = 100 μm). Arrow shows typical hemorrhaging seen in some cases with the Nrf2-/- group. (E) Lesion area from 4 different levels relative to Bregma within the striatum were measured and expressed as percentage of total ipsilateral striatum. Left and right bars for each genotype correspond to left and right hemispheres. No significant differences were seen between hemispheres within the animals. (F) Fluorojade-positive cells were counted in a region of interest within the core of the lesion. Counts from both hemispheres were averaged for each slice. Data represent the mean ± SEM from n = 5 (Nrf2+/+), n = 7 (Nrf2+/-), n = 5 (Nrf2-/-). *p < 0.05, **p < 0.01, ***p < 0.001, compared to wild-type control group, two-tailed t-test.

Figure 2. Inhibition of brain SDH is not different among Nrf2 genotypes 2 h after acute 3-NP injection. Four mice from each genotype were injected with a single dose of 60 mg/kg 3-NP or PBS. 3-NP-injected mice were compared with PBS-injected littermates for each experiment. Animals were sacrificed 2 h after 3-NP injection when the peak of SDH inhibition has been shown to occur (47). Mitochondria samples were prepared from striatum and cortex and used in the SDH assay. A490 was normalized to mitochondrial protein content. Data represent the mean ± SEM from n = 4 mice for each genotype and treatment group. *p < 0.05, compared to PBS injected controls from same genotype, one-way ANOVA with Bonferroni post-hoc test.

Figure 3. Dietary supplementation of tBHQ attenuates 3-NP toxicity in Nrf2+/- mice, but exacerbates toxicity in Nrf2-/- mice. Mice received a tBHQ-supplemented diet for 1 week prior to and during 3-NP administration. Only Nrf2+/- and Nrf2-/- mice were studied since we were interested in observing reduced motor deficit and lesion size with tBHQ treatment, and Nrf2+/+ mice did not develop these phenotypes. (A) No significant differences were observed in body weight of Nrf2+/+ mice between tBHQ and control diet. (B) Nrf2+/- mice never fully adjusted to the tBHQ-supplemented diet where body weight of tBHQ-fed Nrf2-/- mice dropped by 10-20% during 1 week of tBHQ feeding. (C) Control diet and tBHQ-fed Nrf2+/- mice consumed similar amounts of food throughout the experiment. (D) Nrf2+/- mice consumed less food than Nrf2-/- mice with control diet. (E) tBHQ-fed Nrf2+/- mice exhibited reduced motor deficit at the end of the 3-NP treatment regimen. (F) An overall exacerbation of 3-NP induced motor deficits was associated with tBHQ-feeding of Nrf2-/- mice. (G, H) tBHQ-feeding prevented lesion development in Nrf2+/+ mice, but had no effect on Nrf2-/- mice. Lesions are outlined by dotted lines. For the Nrf2+/- group, n = 8 and n = 6 animals were used for control and tBHQ-supplemented diets respectively. For the Nrf2+/- group n = 6 and n = 5 animals were used for control and tBHQ-supplemented diets respectively. Data represents mean ± SEM. *p < 0.05, **p < 0.01, compared to Nrf2+/- mice receiving control diet, one-way ANOVA with Bonferroni post-hoc test.
Figure 4. Ad-Nrf2 infected animals developed smaller lesions than Ad-GFP control animals following 3-NP administration. A.) Immunostaining of GFP with the cell-type specific markers for astrocytes (GFAP, top panel), neurons (NeuN, middle panel) and oligodendrocytes (O4, bottom panel) was first performed to characterize the specificity of viral infection in rats in vivo. Scale bars = 10 μm. B.) Incidence of co-labeling between GFP and the different markers. N represents the total number of GFP+ cells counted for 2 animals. C.) Representative images of GFP expression in the striatum of Ad-GFP infected animals at Bregma (clockwise from top left) 1.00 mm, 0.48 mm, -0.80 mm, and -0.26 mm. Scale bars: 500 μm. D.) Analysis of GFP fluorescence as a percentage of total striatal volume (as determined by the area outlined by a propidium iodide counterstain, n = 11 animals). E.) Quantification of lesion volumes in the ipsilateral (right) and contralateral (left) hemispheres. Data represents mean ± SEM of n = 5 animals per group. * p < 0.05, compared to Ad-GFP infected controls, two-tailed t-test. F.) Representative cresyl violet stained sections at Bregma 0.70 mm for all indicated treatment groups. Arrow indicates receiving the adenoviral vector. Scale bar = 2.5 mm.

Figure 5. 3-NP exposure induces ARE-dependent gene expression in cultured astrocytes. A.) Cultured cortical astrocytes were transiently transfected with a heat-stable placental alkaline phosphatase (hPAP) reporter construct regulated by an ARE-bearing NQO1 promoter (41). The astrocytes were then treated with varying concentrations of 3-NP (1-30 mM) for 2 h in a glucose-free basic salt solution (BSS vehicle), followed by washout. A doubling of hPAP activity was observed 24 h after 10 or 30 mM 3-NP treatment. B.) Expression of ARE-driven hPAP, with vehicle or 3-NP exposure, was reduced to sub-basal levels when astrocytes overexpressed a dominant-negative form of Nrf2 (Ad-Nrf2DN), but not with overexpression of a GFP control (Ad-GFP) (6). ARE-driven hPAP was induced by 24 h of tBHQ exposure and maximally increased with Ad-Nrf2 infection. Data represent the mean ± SEM from three independent experiments. C.) Semi-quantitative RT-PCR confirmed that astrocytes treated with 30 mM 3-NP expressed more mRNAs from prototypic Nrf2 target genes including NAD(P)H:quinone oxidoreductase (NQO1), γ-glutamylcysteine synthetase (GCLC), and the cystine/glutamate exchanger (xCT). DNA templates were serially diluted to ensure that band intensities were observed within the linear range of the PCR reaction (Suppl. Fig. 2). As controls, Ad-Nrf2 and Ad-Nrf2DN infected cultures were also evaluated with RT-PCR. In all cases, the mRNA levels were induced with Nrf2 overexpression and suppressed with Nrf2DN overexpression. RT-PCR experiments were reproduced three times with similar results. D.) Cultures treated with 30 mM 3-NP produced more total intracellular GSH than vehicle treated controls. GSH induction was blocked with Ad-Nrf2DN infection, but not Ad-GFP control. E.) Western blot analysis shows protein expression of heme oxygenase-1 (HO-1) was induced with 30 mM 3-NP treatment in Ad-GFP infected cultures. Both basal and induced expression of HO-1 was largely blocked with Ad-Nrf2DN infection. D.) Densitometric analyses of HO-1 protein levels. GSH and HO-1 data represent the mean ± SEM from three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, two-tailed paired t-test.

Figure 6. 3-NP promotes nuclear translocation of Nrf2-GFP. A.) COS-1 cells were transiently transfected with Nrf2-GFP (N-terminal fusion to Nrf2) with and without Keap1-FLAG (N-terminal fusion to Nrf2). Consistent with previous studies, overexpressed Nrf2-GFP was almost exclusively localized to the nucleus unless co-expressed with its cytoplasmic regulator Keap1 (top row).13,43) COS-1 cells co-expressing Nrf2-GFP and Keap1-FLAG were evaluated after treatment with 3-NP or BSS vehicle control. The proportion of cells exhibiting nuclear-enriched Nrf2-GFP was significantly higher in 3-NP-treated cultures, when compared to vehicle control. 3-NP also appeared to cause a transient aggregation of some Keap1-FLAG and Nrf2-GFP in the cytoplasm (bottom row). Treatment with 20 μM tBHQ for 4 h, as a positive control, also robustly increased nuclear localization of Nrf2-GFP. B.) Summary of Nrf2-GFP localization in response to tBHQ and 3-NP. C.) Both Nrf2-GFP and Keap1-FLAG constructs were functional, as assessed by their ability to augment and suppress ARE-driven hPAP expression, respectively. Data represents three separate experiments by an experimenter blinded to the treatment conditions (total cells evaluated: n = 119 and n = 158, BSS and 3-NP-treated cells, respectively). * p < 0.05, two-tailed paired t-test.

Supplementary Figure 1. Behavioural scores and weight are highly correlated with lesion volume during 3-NP challenge. A B.) Lesion volume was plotted against either behavioural scores obtained 1.5 days after the last 3-NP injection or percentage start weight 1.5 days after the last 3-NP injection. Strong correlations were found...
with both comparisons. Data represent the mean ± SEM (animals per genotype: Nrf2+/+ = 5, Nrf2+/− = 7, Nrf2−/− = 5). *** p < 0.0001, r = 0.867 (A), ** p < 0.001, r = -0.693 (B), Spearman test.

**Supplementary Figure 2.** RT-PCR images were collected within the linear range of the PCR reaction. RNA extracted from vehicle, 3-NP treated glia (3 and 30 mM) was used for standard semi-quantitative RT-PCR. Appropriate primers were used to determine relative quantities of Nrf2, NQO1, GCLC, xCT transcripts, and these values were normalized with actin density (A-D). E.) 3-NP treatment did not affect actin mRNA levels. cDNA templates were serially diluted to ensure that band intensities were observed within the linear range of the PCR reaction. Densitometric analyses were performed with ImageJ Software (NIH). Data shown is representative of 3 independent experiments with similar results.

Table 1. Effects of Nrf2 genotype on basal and tBHQ-induced levels of antioxidant/detoxification markers in striatum, cortex, and liver

|                  | Basal Phase 2 Enzyme Levels | tBHQ-induced Phase 2 Enzyme Levels (% control) |
|------------------|-----------------------------|-----------------------------------------------|
|                  | Striatum | Cortex | Liver | Striatum | Cortex | Liver |
| **GST**          | 72.9 ± 6.9 | 57.4 ± 4.7 ** | 65.9 ± 6.2 | 49.0 ± 4.9 *** | 290.4 ± 35.8 | 195.0 ± 21.2 ** |
| **NQO1**         | 46.7 ± 1.3 | 37.3 ± 1.6 ** | 29.7 ± 2.6 | 24.0 ± 1.2 * | 18.0 ± 4.0 | 5.2 ± 1.4 ** |
| **GSH**          | 28.5 ± 3.4 | 30.2 ± 4.8 | 23.1 ± 4.1 | 26.5 ± 3.9 | 110.5 ± 15.9 | 70.3 ± 9.3 * |
| **LDH**          | 590.7 ± 49.6 | 601.5 ± 29.4 | 628.6 ± 27.9 | 686.8 ± 53.2 | 1094.6 ± 51.0 | 1234.7 ± 79.5 |

Basal Phase 2 Enzyme Levels. GST, NQO1, and LDH activities from tissue extracts are expressed as nmol/min/mg protein, and total GSH content is expressed as μg GSH + GSSG / mg protein. Data are represented as mean ± SEM. N = 6 animals, for both Nrf2+/+ and Nrf2−/− groups. * p < 0.05, ** p < 0.01, *** p < 0.001, compared to wild-type littermates, two-tailed paired t-test.

**tBHQ-induced Phase 2 Enzyme Levels.** Enzyme activities and GSH content were measured after 7 days of tBHQ feeding (1% w/w in mouse chow), and expressed as a percentage of values obtained from littermates receiving control diet. N = 2, 4, and 4 littermate pairs for Nrf2+/+, Nrf2−/−, and Nrf2+/− groups were used, respectively. # p < 0.05, compared littermates with same genotype receiving control diet, two-tailed paired t-test.
Figure 1

A

Cumulative Behavioural Score

B

Animal Weight (% start weight)

C

Bregma (mm)  
+/+  +/−  −/−
1.10
0.40
−0.26
−0.92

D

Cresyl violet  Fluorojade

+/+

+/−

−/−

E

Lesion Area (% total striatum)

F

Fluorojade labeled cells / image

Bregma  1.10  0.40  −0.26  −0.92

Downloaded from http://www.jbc.org by guest on July 10, 2020
Figure 2

[Bar graph showing color density (A490/mg protein) for Cortex and Striatum under various conditions including PBS-injected and 3-NP-injected. Star symbols indicate statistical significance.]
Figure 4
Figure 5

(A) hPAP activity (% vehicle control) vs. 3-NP concentration (mM).

(B) hPAP activity (% Ad-GFP + vehicle control) vs. 3-NP (mM) for Ad-GFP, Ad-Nrf2DN, and Ad-Nrf2.

(C) Western blot analysis of Nrf2, NQO1, GCLC, XCT, and Actin under different conditions.

(D) My GSH + GSSG/mg protein vs. 3-NP (mM) for Ad-GFP, Ad-Nrf2DN, Ad-Nrf2, and Ad-Nrf2DN.

(E) Western blot of HO-1 and Actin under different conditions.

(F) Actin-normalized HO-1 density (% Ad-GFP + vehicle control) vs. 3-NP (mM) for Ad-GFP, Ad-Nrf2DN, Ad-Nrf2, and Ad-Nrf2DN.
Figure 6

A

B

C

Nrf2-GFP + Keap1-FLAG

Nrf2-GFP + Keap1-FLAG

Nrf2-GFP + Keap1-FLAG

Nrf2-GFP + Keap1-FLAG

Anti-GFP

Anti-FLAG

Overlay

% of total cells counted

Nrf2-GFP Keap1-FLAG Treatment

Cytoplasm-enriched

Nucleus-enriched

DMSO

IbHq

BSS

3-NP

ARE-driven hPAP expression (% Control)

Nrf2 wild-type

Nrf2-GFP

1-cell

Keap1-FLAG
Supplementary Figure 1

A

B
Supplementary Figure 2

A. Nrf2

B. NQO1

C. GCLC

D. XCT

E. Actin

- - - - Vehicle

- - - 3mM 3-NP

- - - 30mM 3-NP
Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo
Andy Y. Shih, Sophie Imbeault, Vilte Barakauskas, Heidi Erb, Lei Jiang, Ping Li and Timothy H. Murphy

J. Biol. Chem. published online April 19, 2005

Access the most updated version of this article at doi: 10.1074/jbc.M414635200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2005/05/05/M414635200.DC1